ArticleInternational journal of pharmaceutics: X2026
Unlocking the acquired ultraviolet-resistance and enhanced antioxidant potential of pterostilbene-loaded pharmaceutical-dots.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultraviolet (UV) radiation, particularly UVA and UVB, induces skin damage through oxidative stress and inflammation. However, existing UV protection materials fail to simultaneously block UV rays and scavenge reactive oxygen species (ROS). To address this dual challenge, we developed pterostilbene (PTE)-loaded Tween 80 micelles, designated Tw80-based pharmaceutical dots (PTE-Tw80@PDs). This nanosystem exploited the chromophore's aggregation induced emission property: it absorbs UV radiation and re-emit it as harmless longer-wavelength light (410 nm), while delivering potent antioxidant activity. Physicochemical characterization confirmed PTE-Tw80@PDs to exhibit a narrow size distribution (∼10 nm), significantly enhanced fluorescence, and broad-spectrum UV attenuation (200-400 nm). In vitro assays demonstrated superior ROS scavenging over free PTE, reduced UV-induced cytotoxicity in HUVEC and HaCaT cells, and excellent biocompatibility based on Tween 80. This nanoplatform integrates UV shielding, ROS neutralization, and safe delivery, offering a promising strategy for comprehensive photoprotection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.